While PD-L1 expression and the tumor mutational burden were not associated with better outcomes, compared to melanoma and NSCLC, biomarkers from TME are promising but still need further investigation and validation in RCC [4, 5, 24, 32]. This evidence concerns the gene CD274 and neoplasm.